Literature DB >> 16421127

Peripheral neuropathies in Waldenström's macroglobulinaemia.

T Levine1, A Pestronk, J Florence, M T Al-Lozi, G Lopate, T Miller, I Ramneantu, W Waheed, M Stambuk, M J Stone, R Choksi.   

Abstract

OBJECTIVE: We sought to determine the prevalence, clinical features, and laboratory characteristics of polyneuropathies in Waldenström's macroglobulinaemia (WM), a malignant bone marrow disorder with lymphocytes that produce monoclonal IgM.
METHODS: We prospectively studied 119 patients with WM and 58 controls. Medical history was taken, and neurological examinations, electrodiagnostic tests, and serum studies were performed by different examiners who were blinded to results except the diagnosis of WM.
RESULTS: Polyneuropathy symptoms, including discomfort and sensory loss in the legs, occurred more frequently (p<0.001) in patients with WM (47%) than in controls (9%). Patients with WM had 35% lower quantitative vibration scores, and more frequent pin loss (3.4 times) and gait disorders (5.5 times) than controls (all p<0.001). Patients with IgM binding to sulphatide (5% of WM) had sensory axon loss; those with IgM binding to myelin associated glycoprotein (MAG) (4% of WM) had sensorimotor axon loss and demyelination. Patients with WM with IgM binding to sulphatide (p<0.005) or MAG (p<0.001) had more severe sensory axon loss than other patients with WM. Demyelination occurred in 4% of patients with WM with no IgM binding to MAG. Age related reductions in vibration sense and sural SNAP amplitudes were similar ( approximately 30%) in WM and controls.
CONCLUSIONS: Peripheral nerve symptoms and signs occur more frequently in patients with WM than controls, involve sensory modalities, and are often associated with gait disorders. IgM binding to MAG or sulphatide is associated with a further increase in the frequency and severity of peripheral nerve involvement. Age related changes, similar to those in controls, add to the degree of reduced nerve function in patients with WM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421127      PMCID: PMC2077569          DOI: 10.1136/jnnp.2005.071175

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

Review 1.  Waldenström's macroglobulinemia: clinical features, complications, and management.

Authors:  M A Dimopoulos; P Panayiotidis; L A Moulopoulos; P Sfikakis; M Dalakas
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Anti-sulfatide IgM antibodies in peripheral neuropathy.

Authors:  M Carpo; N Meucci; S Allaria; P Marmiroli; S Monaco; A Toscano; S Simonetti; G Scarlato; E Nobile-Orazio
Journal:  J Neurol Sci       Date:  2000-06-15       Impact factor: 3.181

3.  Reactivity of sera and isolated monoclonal IgM from patients with Waldenström's macroglobulinaemia with peripheral nerve myelin.

Authors:  H Harbs; M Arfmann; E Frick; C Hörmann; U Wurster; U Patzold; E Stark; H Deicher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

4.  Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies.

Authors:  E Nobile-Orazio; N Meucci; L Baldini; A Di Troia; G Scarlato
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

Review 5.  Paraproteinemic neuropathies.

Authors:  A Vital
Journal:  Brain Pathol       Date:  2001-10       Impact factor: 6.508

6.  Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy.

Authors:  S Monaco; B Bonetti; S Ferrari; G Moretto; E Nardelli; F Tedesco; T E Mollnes; E Nobile-Orazio; E Manfredini; L Bonazzi
Journal:  N Engl J Med       Date:  1990-03-08       Impact factor: 91.245

7.  Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia.

Authors:  E Nobile-Orazio; E Francomano; R Daverio; S Barbieri; P Marmiroli; E Manfredini; M Carpo; M Moggio; G Legname; L Baldini
Journal:  Ann Neurol       Date:  1989-10       Impact factor: 10.422

8.  Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies.

Authors:  S Erb; F Ferracin; P Fuhr; K M Rösler; C W Hess; T Kuntzer; J Bogousslavsky; R Sztajzel; A J Steck
Journal:  J Neurol       Date:  2000-10       Impact factor: 4.849

9.  Anti-myelin-associated glycoprotein antibodies and endoneurial cryoglobulin deposits responsible for a severe neuropathy.

Authors:  A Vital; A Favereaux; P Martin-Dupont; J L Taupin; K Petry; A Lagueny; M H Canron; C Vital
Journal:  Acta Neuropathol       Date:  2001-10       Impact factor: 17.088

10.  Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy.

Authors:  T Ariga; T Kohriyama; L Freddo; N Latov; M Saito; K Kon; S Ando; M Suzuki; M E Hemling; K L Rinehart
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

View more
  10 in total

1.  Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.

Authors:  Carlo Canepa
Journal:  BMJ Case Rep       Date:  2019-03-31

2.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

3.  [18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia.

Authors:  Thomas A Fox; Michael Lunn; Ashutosh Wechalekar; Jamshed Bomanji; Simon Wan; Shirley D'Sa
Journal:  Haematologica       Date:  2018-04-12       Impact factor: 9.941

4.  Clinical, electrophysiological and immunological study of peripheral nerves in Egyptian patients with monoclonal gammopathies.

Authors:  Mohamed M El-Difrawy; Nadia E Zaki; Hazem M Marouf; Mona W Ayad; Ahmed M Farag
Journal:  Int J Hematol       Date:  2011-12-17       Impact factor: 2.490

5.  Neurological picture. Paravertebral Waldenström's macroglobulinaemia presenting as pseudoclaudication.

Authors:  S W Taylor; M Q Lacy; D F Black; C J Klein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-01-08       Impact factor: 10.154

6.  The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.

Authors:  Christopher J Klein; Joon-Shik Moon; Michelle L Mauermann; Steven R Zeldenrust; Yanhong Wu; Angela Dispenzieri; Peter J Dyck
Journal:  Can J Neurol Sci       Date:  2011-03       Impact factor: 2.104

7.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Authors:  Jorge J Castillo; Ramon Garcia-Sanz; Evdoxia Hatjiharissi; Robert A Kyle; Xavier Leleu; Mary McMaster; Giampaolo Merlini; Monique C Minnema; Enrica Morra; Roger G Owen; Stephanie Poulain; Marvin J Stone; Constantine Tam; Marzia Varettoni; Meletios A Dimopoulos; Steven P Treon; Efstathios Kastritis
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

8.  Splenic re-irradiation for waldenstrőm's macroglobulinemia.

Authors:  Zhou Wei; Yu Yanxia; Xu Ying; Wang Han; Jiang Yuhua
Journal:  Radiat Oncol       Date:  2012-04-12       Impact factor: 3.481

9.  Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report.

Authors:  Lesia Rozłucka; Elżbieta Semik-Grabarczyk; Marta Pietrukaniec; Agnieszka Żak-Gołąb; Małgorzata Grabarczyk; Sebastian Grosicki; Michał Holecki
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

10.  Waldenström's macroglobulinemia presenting with bilateral vestibular loss: a case report.

Authors:  Andrea Castellucci; Gianluca Piras; Cristina Brandolini; Giovanni Carlo Modugno; Gian Gaetano Ferri
Journal:  Braz J Otorhinolaryngol       Date:  2015-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.